NCT00389805View on ClinicalTrials.gov

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

June 30, 2007

Conditions
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

bortezomib

DRUG

pemetrexed disodium

GENETIC

gene expression analysis

GENETIC

mutation analysis

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

flow cytometry

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of California, Davis

OTHER

NCT00389805 - Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | Biotech Hunter | Biotech Hunter